Novo Nordisk is further strengthening its obesity production in the U. S. by injecting $4. 1 billion for a momentary fill-and-finish facility in Clayton. . .
Access a limited number of individual articles and newsletters to go straight to your inbox.
© Endpoint News 2024
We will email you a link to set a new password. Please note that this link is for one-time use only and valid for 24 hours.
Biopharmaceuticals
Want unlimited access? Sign up for a subscription plan.